AIM
EBS icon

Anchor Investment Management’s Emergent Biosolutions EBS Stock Holding History

Anchor Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,395
Closed -$130K – 954
2021
Q1 		$130K Buy
1,395
+1,130
+426% +$116K 0.02% 404
2020
Q4 		$23.7K Buy
+265
New +$24.3K ﹤0.01% 575

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anchor Investment Management's EBS Position: Q2 2021 in Review

Anchor Investment Management sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 1,395 shares — an estimated $130K sold.

Anchor Investment Management first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $130K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Anchor Investment Management reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Anchor Investment Management sold 1,395 Emergent Biosolutions shares in Q2 2021, an estimated $130K.
  • Anchor Investment Management first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
  • Anchor Investment Management's Emergent Biosolutions position peaked at $130K in Q1 2021.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Anchor Investment Management's 13F filing for Q2 2021, filed 2 Jan 2024.